Sarcoma Therapeutics Market size is set to grow by USD 1.11 billion from 2024-2028, Patient assistance programs boost the market, Technavio [Yahoo! Finance]
Adaptimmune Therapeutics plc - American Depositary Shares (ADAP)
Last adaptimmune therapeutics plc - american depositary shares earnings: 5/9 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.adaptimmune.com/phoenix.zhtml?c=253991&p=irol-newsarticle&id=2255800
Company Research
Source: Yahoo! Finance
The market is estimated to grow at a CAGR of 8.51% during the forecast period. Patient assistance programs is driving market growth, with a trend towards R and D of new drugs for oh treatment. However, high treatment costs poses a challenge. Key market players include Adaptimmune Therapeutics plc, Advenchen Laboratories LLC, Agenus Inc., Agios Inc., Athenex Inc., Bayer AG, Bristol Myers Squibb Co., Eisai Co. Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, Ipsen Pharma, Johnson and Johnson Services Inc., Karyopharm Therapeutics Inc., LadRx Corp., Mirati Therapeutics Inc., Novartis AG, Pfizer Inc., PharmaMar SA, and SillaJen Co. Ltd.. Get a detailed analysis on regions, market segments, customer landscape, and companies- View the snapshot of this report Sarcoma Therapeutics Market Scope Report Coverage Details Base year Historic period Forecast period Growth momentum & CAGR Accelerate at a CAGR of 8.51% Market growth 2024-2028 USD 1110.8 million Market structure
Show less
Read more
Impact Snapshot
Event Time:
ADAP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADAP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADAP alerts
High impacting Adaptimmune Therapeutics plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ADAP
News
- Adaptimmune to Participate in Scientific and Medical Conferences this November and December [Yahoo! Finance]Yahoo! Finance
- OTC Markets Hosts Virtual Investor Presentation with Adrian Rawcliffe, CEO of Adaptimmune Therapeutics, and Michael Kim, Senior Analyst at Zacks SCR [Yahoo! Finance]Yahoo! Finance
- Immuno-Oncology 360º Announces 2025 Keynotes and Featured Speakers for the 11th Annual Meeting in BostonPR Web
- ReCode Announces Two Key Additions to Scientific Advisory BoardBusiness Wire
- Adaptimmune Therapeutics plc's (NASDAQ:ADAP) top owners are individual investors with 39% stake, while 28% is held by institutions [Yahoo! Finance]Yahoo! Finance
ADAP
Analyst Actions
- 8/13/24 - HC Wainwright
ADAP
Sec Filings
- 11/1/24 - Form 8-K
- 9/23/24 - Form 8-K
- 8/12/24 - Form 10-Q
- ADAP's page on the SEC website